PDCD1 and gastric cancer: By targeting key immune checkpoints such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1), these agents have shown remarkable efficacy in patients with advanced gastric cancer, leading to durable responses and improved survival outcomes (12).